2025 Q4 -tulosraportti
Äänite tulossa
Tänään
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
569
Myynti
Määrä
803
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 631 | - | - | ||
| 213 | - | - | ||
| 93 | - | - | ||
| 312 | - | - | ||
| 299 | - | - |
Ylin
21,3VWAP
Alin
19,02VaihtoMäärä
58,5 2 954 724
VWAP
Ylin
21,3Alin
19,02VaihtoMäärä
58,5 2 954 724
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
2 t sitten2 t sittenWhat This Drop Does NOT Indicate It does not suggest: ❌ Financing risk ❌ Going concern ❌ Partner collapse ❌ Clinical failure ❌ Accounting issue Balance sheet is extremely strong (SEK 580m cash) This is not distress selling.
·2 t sittenWell, this proves how Alternative Intelligence (AI) can be misused: Saniona Q4 revenue plummets. That the annual result and revenue explode and have not been larger, does not interest AI and apparently thus causes some to abandon their investments. But, it is a sound case and I hope this doesn't make TF sell projects before phase 1 is completed.
·4 t sittenThis is an obvious buying opportunity when the decline has stopped. It will come back strongly. Maybe already at 11 today, but otherwise when/if they come with updates on their product development/cooperation agreements.
·4 t sitten · MuokattuWell then - maybe we should go down to 12-14, where I will start buying again. It is at least a more reasonable level in their current situation, where they are slowly about to burn hundreds of millions in high-risk projects. 46 mill in a quarter - as far as I know without major projects ongoing - that still adds up to something over 4 quarters. Maybe people will realize it at some point !? Yes - it has a lot of money (De-risk) - but they have chosen to continue with all 3 programs (expensive) further and longer than usual (increase-risk). Some hard-core Sanionaister insist that existing agreements and cash reserves combined have reduced the risk while I - and very few others - even after more than a decade with Saniona - believe that the risk-ratio (risk/price) is no longer quite as attractive. I am at least putting my risk investments into others where I find the ratio more attractive. The next price-influencing (upwards) factor is the upcoming quite certain milestones on the recent agreements - and then a decision in Mexico which can go either way. A rejection (10-14) and I buy - an approval, then we will probably be back at 20-25 and far too expensive for my taste.- ·4 t sittenGood report and nice that they can afford to finance their own research, one cannot say that about compared biotech companies. Future is bright with milestone payments and new agreements. Have to say it, so everything doesn't drown in meaningless negativity ;-)·4 t sitten · Muokattu:-) - there doesn't seem to be much negativity around Saniona - if one tries something that doesn't involve a doubling in a short time - and thoughts of manipulation, if it falls, then one quickly gets a bucket of l... in the head. So I don't think you should be so nervous about "negativity" - everyone who has a reasonably objective view of Saniona has long since stopped commenting :-). You can just try to scroll through the comments on the report :-) - I think you will get confirmation that the next risk-free future looks VERY bright and promising, and any fall is due to people not having properly understood the "case" - so you can completely relax, and have a calm weekend.·2 t sitten · MuokattuFirst of all - praise (and thanks) for at least commenting in a proper tone - it greatly encourages the desire to participate in the debate. :-) - I don't perceive myself as negative - I try my best - but it's clearly not good enough :-) - just to be objective. So let me repeat: I am super positive about Saniona's development, I just think the share price development has skyrocketed, and risk/reward is currently not that attractive in my world compared to other investments. My estimate is they will need 2+mia until 2030 + ongoing operations, which, if we take 2025Q4 at -46mill, can amount to 200+250 mill/year = over 3 mia until 2030, when realistically there might be something. And if they take 1 of the compounds through phase 3, I would guess it's even more. And if one also - quite realistically - includes that at least 1, maybe 2 of the projects will fail - including possibly 1 of the out-licensed/sold ones - then I don't think it's reflected in a share price of 20. Unfortunately, I don't have unlimited funds (then I probably wouldn't be interested in companies like Saniona etc.), so I have to prioritize a bit where I put my money. And currently, I see greater risk/reward in e.g. Moberg Pharma, Infant Bacterial and Xspray than in Saniona. Ascelia and Egetis also "compete" for the funds I have allocated to the "risk" category of my PF. For me to consider the Saniona case to be just as attractive, we need to go down to around 12-14 - then I believe it can be considered as an alternative/supplement to the 3/(5) mentioned. So it's just an expression that, compared to other investment opportunities, I don't think a share price of 20 is particularly attractive for Saniona - but others do - perhaps with more funds than me, so they have reached max per share on the other positions within the risk part of the total PF - and that's fair enough. It just seems like it's not fair to think that a share price of 20 for Saniona is too high? - and I think that's strange - and dangerous, when one develops an almost "religious" relationship with one's investments. For the same reason, I didn't bother with the FB group anymore, for example (even though it surprised me that it actually WAS possible to "bully" me out :-) :-). It just became too much of a clown show for me after all. Here it meant more that Jørgen Drejer personally wrote to me and thanked me for the many years as a "passionate" shareholder" - even though I was a tiny little one of those - he reads along in both FB groups (the old one probably died a bit) and is also in the Discord Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 2 t sitten2 t sittenWhat This Drop Does NOT Indicate It does not suggest: ❌ Financing risk ❌ Going concern ❌ Partner collapse ❌ Clinical failure ❌ Accounting issue Balance sheet is extremely strong (SEK 580m cash) This is not distress selling.·2 t sittenWell, this proves how Alternative Intelligence (AI) can be misused: Saniona Q4 revenue plummets. That the annual result and revenue explode and have not been larger, does not interest AI and apparently thus causes some to abandon their investments. But, it is a sound case and I hope this doesn't make TF sell projects before phase 1 is completed.
- ·4 t sittenThis is an obvious buying opportunity when the decline has stopped. It will come back strongly. Maybe already at 11 today, but otherwise when/if they come with updates on their product development/cooperation agreements.
- ·4 t sitten · MuokattuWell then - maybe we should go down to 12-14, where I will start buying again. It is at least a more reasonable level in their current situation, where they are slowly about to burn hundreds of millions in high-risk projects. 46 mill in a quarter - as far as I know without major projects ongoing - that still adds up to something over 4 quarters. Maybe people will realize it at some point !? Yes - it has a lot of money (De-risk) - but they have chosen to continue with all 3 programs (expensive) further and longer than usual (increase-risk). Some hard-core Sanionaister insist that existing agreements and cash reserves combined have reduced the risk while I - and very few others - even after more than a decade with Saniona - believe that the risk-ratio (risk/price) is no longer quite as attractive. I am at least putting my risk investments into others where I find the ratio more attractive. The next price-influencing (upwards) factor is the upcoming quite certain milestones on the recent agreements - and then a decision in Mexico which can go either way. A rejection (10-14) and I buy - an approval, then we will probably be back at 20-25 and far too expensive for my taste.
- ·4 t sittenGood report and nice that they can afford to finance their own research, one cannot say that about compared biotech companies. Future is bright with milestone payments and new agreements. Have to say it, so everything doesn't drown in meaningless negativity ;-)·4 t sitten · Muokattu:-) - there doesn't seem to be much negativity around Saniona - if one tries something that doesn't involve a doubling in a short time - and thoughts of manipulation, if it falls, then one quickly gets a bucket of l... in the head. So I don't think you should be so nervous about "negativity" - everyone who has a reasonably objective view of Saniona has long since stopped commenting :-). You can just try to scroll through the comments on the report :-) - I think you will get confirmation that the next risk-free future looks VERY bright and promising, and any fall is due to people not having properly understood the "case" - so you can completely relax, and have a calm weekend.·2 t sitten · MuokattuFirst of all - praise (and thanks) for at least commenting in a proper tone - it greatly encourages the desire to participate in the debate. :-) - I don't perceive myself as negative - I try my best - but it's clearly not good enough :-) - just to be objective. So let me repeat: I am super positive about Saniona's development, I just think the share price development has skyrocketed, and risk/reward is currently not that attractive in my world compared to other investments. My estimate is they will need 2+mia until 2030 + ongoing operations, which, if we take 2025Q4 at -46mill, can amount to 200+250 mill/year = over 3 mia until 2030, when realistically there might be something. And if they take 1 of the compounds through phase 3, I would guess it's even more. And if one also - quite realistically - includes that at least 1, maybe 2 of the projects will fail - including possibly 1 of the out-licensed/sold ones - then I don't think it's reflected in a share price of 20. Unfortunately, I don't have unlimited funds (then I probably wouldn't be interested in companies like Saniona etc.), so I have to prioritize a bit where I put my money. And currently, I see greater risk/reward in e.g. Moberg Pharma, Infant Bacterial and Xspray than in Saniona. Ascelia and Egetis also "compete" for the funds I have allocated to the "risk" category of my PF. For me to consider the Saniona case to be just as attractive, we need to go down to around 12-14 - then I believe it can be considered as an alternative/supplement to the 3/(5) mentioned. So it's just an expression that, compared to other investment opportunities, I don't think a share price of 20 is particularly attractive for Saniona - but others do - perhaps with more funds than me, so they have reached max per share on the other positions within the risk part of the total PF - and that's fair enough. It just seems like it's not fair to think that a share price of 20 for Saniona is too high? - and I think that's strange - and dangerous, when one develops an almost "religious" relationship with one's investments. For the same reason, I didn't bother with the FB group anymore, for example (even though it surprised me that it actually WAS possible to "bully" me out :-) :-). It just became too much of a clown show for me after all. Here it meant more that Jørgen Drejer personally wrote to me and thanked me for the many years as a "passionate" shareholder" - even though I was a tiny little one of those - he reads along in both FB groups (the old one probably died a bit) and is also in the Discord Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
569
Myynti
Määrä
803
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 631 | - | - | ||
| 213 | - | - | ||
| 93 | - | - | ||
| 312 | - | - | ||
| 299 | - | - |
Ylin
21,3VWAP
Alin
19,02VaihtoMäärä
58,5 2 954 724
VWAP
Ylin
21,3Alin
19,02VaihtoMäärä
58,5 2 954 724
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 2 t sitten2 t sittenWhat This Drop Does NOT Indicate It does not suggest: ❌ Financing risk ❌ Going concern ❌ Partner collapse ❌ Clinical failure ❌ Accounting issue Balance sheet is extremely strong (SEK 580m cash) This is not distress selling.·2 t sittenWell, this proves how Alternative Intelligence (AI) can be misused: Saniona Q4 revenue plummets. That the annual result and revenue explode and have not been larger, does not interest AI and apparently thus causes some to abandon their investments. But, it is a sound case and I hope this doesn't make TF sell projects before phase 1 is completed.
- ·4 t sittenThis is an obvious buying opportunity when the decline has stopped. It will come back strongly. Maybe already at 11 today, but otherwise when/if they come with updates on their product development/cooperation agreements.
- ·4 t sitten · MuokattuWell then - maybe we should go down to 12-14, where I will start buying again. It is at least a more reasonable level in their current situation, where they are slowly about to burn hundreds of millions in high-risk projects. 46 mill in a quarter - as far as I know without major projects ongoing - that still adds up to something over 4 quarters. Maybe people will realize it at some point !? Yes - it has a lot of money (De-risk) - but they have chosen to continue with all 3 programs (expensive) further and longer than usual (increase-risk). Some hard-core Sanionaister insist that existing agreements and cash reserves combined have reduced the risk while I - and very few others - even after more than a decade with Saniona - believe that the risk-ratio (risk/price) is no longer quite as attractive. I am at least putting my risk investments into others where I find the ratio more attractive. The next price-influencing (upwards) factor is the upcoming quite certain milestones on the recent agreements - and then a decision in Mexico which can go either way. A rejection (10-14) and I buy - an approval, then we will probably be back at 20-25 and far too expensive for my taste.
- ·4 t sittenGood report and nice that they can afford to finance their own research, one cannot say that about compared biotech companies. Future is bright with milestone payments and new agreements. Have to say it, so everything doesn't drown in meaningless negativity ;-)·4 t sitten · Muokattu:-) - there doesn't seem to be much negativity around Saniona - if one tries something that doesn't involve a doubling in a short time - and thoughts of manipulation, if it falls, then one quickly gets a bucket of l... in the head. So I don't think you should be so nervous about "negativity" - everyone who has a reasonably objective view of Saniona has long since stopped commenting :-). You can just try to scroll through the comments on the report :-) - I think you will get confirmation that the next risk-free future looks VERY bright and promising, and any fall is due to people not having properly understood the "case" - so you can completely relax, and have a calm weekend.·2 t sitten · MuokattuFirst of all - praise (and thanks) for at least commenting in a proper tone - it greatly encourages the desire to participate in the debate. :-) - I don't perceive myself as negative - I try my best - but it's clearly not good enough :-) - just to be objective. So let me repeat: I am super positive about Saniona's development, I just think the share price development has skyrocketed, and risk/reward is currently not that attractive in my world compared to other investments. My estimate is they will need 2+mia until 2030 + ongoing operations, which, if we take 2025Q4 at -46mill, can amount to 200+250 mill/year = over 3 mia until 2030, when realistically there might be something. And if they take 1 of the compounds through phase 3, I would guess it's even more. And if one also - quite realistically - includes that at least 1, maybe 2 of the projects will fail - including possibly 1 of the out-licensed/sold ones - then I don't think it's reflected in a share price of 20. Unfortunately, I don't have unlimited funds (then I probably wouldn't be interested in companies like Saniona etc.), so I have to prioritize a bit where I put my money. And currently, I see greater risk/reward in e.g. Moberg Pharma, Infant Bacterial and Xspray than in Saniona. Ascelia and Egetis also "compete" for the funds I have allocated to the "risk" category of my PF. For me to consider the Saniona case to be just as attractive, we need to go down to around 12-14 - then I believe it can be considered as an alternative/supplement to the 3/(5) mentioned. So it's just an expression that, compared to other investment opportunities, I don't think a share price of 20 is particularly attractive for Saniona - but others do - perhaps with more funds than me, so they have reached max per share on the other positions within the risk part of the total PF - and that's fair enough. It just seems like it's not fair to think that a share price of 20 for Saniona is too high? - and I think that's strange - and dangerous, when one develops an almost "religious" relationship with one's investments. For the same reason, I didn't bother with the FB group anymore, for example (even though it surprised me that it actually WAS possible to "bully" me out :-) :-). It just became too much of a clown show for me after all. Here it meant more that Jørgen Drejer personally wrote to me and thanked me for the many years as a "passionate" shareholder" - even though I was a tiny little one of those - he reads along in both FB groups (the old one probably died a bit) and is also in the Discord Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
569
Myynti
Määrä
803
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 631 | - | - | ||
| 213 | - | - | ||
| 93 | - | - | ||
| 312 | - | - | ||
| 299 | - | - |
Ylin
21,3VWAP
Alin
19,02VaihtoMäärä
58,5 2 954 724
VWAP
Ylin
21,3Alin
19,02VaihtoMäärä
58,5 2 954 724
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 969 049 | 2 969 049 | 0 | 0 |